12 terminated. 12 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Terminated 12 |
| Phase 2 | 2 | Terminated 2 |
Follow Hyperphagia: new trials by email Literature Review of Hyperphagia trials Research Report on Hyperphagia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial Placebo, ARD-101 - Hyperphagia, Prader-Willi Syndrome | Phase 3 | Terminated | Aardvark Therapeutics, Inc. | 68 | 2024-12-20 | 2026-06-30 |
| The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial ARD-101 - Hyperphagia, Prader-Willi Syndrome | Phase 3 | Terminated | Aardvark Therapeutics, Inc. | 19 | 2024-07-23 | 2026-06-30 |
| Oral Naltrexone In Pediatric Eating Disorders Naltrexone Hydrochloride, Control - Anorexia Nervosa/Bulimia, Anorexia in Adolescence | Phase 2 / Phase 3 | Terminated | Rosemary Claire Roden | 9 | 2022-04-22 | 2025-08-19 |
| Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome Livoletide, Placebo - Prader-Willi Syndrome, Hyperphagia | Phase 2 / Phase 3 | Terminated | Millendo Therapeutics SAS | 158 | 2019-03-25 | 2021-02-17 |
| Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Standard care of parenteral nutrition, Parenteral over night nutrition, Cetuximab - Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV | Phase 3 | Terminated | Arbeitsgemeinschaft medikamentoese Tumortherapie | 8 | 2017-02-03 | 2020-05-01 |
| Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20% - Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days | Phase 3 | Terminated | Fresenius Kabi | 204 | 2015-12-01 | 2022-01-05 |
| Influence of Fish Oil Based Intravenous Fat Emulsions on the Epidermal Barrier Function soybean oil (SO)-based IVFE (Medialipide), fish oil (FO)-containing IVFE (Lipidem) - Intestinal Diseases | Phase 3 | Terminated | Hospices Civils de Lyon | 13 | 2015-01-01 | 2018-02-28 |
| Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome ZGN-440 for Injectable Suspension, ZGN-440 Placebo for Injectable Suspension - Prader-Willi Syndrome, Obesity | Phase 3 | Terminated | Zafgen, Inc. | 108 | 2014-09-01 | 2017-01-26 |
| Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition Soybean oil (Standard treatment), Soybean oil + Fish oil - Total Parenteral Nutrition-induced Cholestasis | Phase 3 | Terminated | Johane Allard | 2 | 2012-02-01 | 2016-05-12 |
| Total Parenteral Nutrition Associated Cholestasis (TPNAC) and Plasma Amino Acid Levels in Neonates Primene 10 % from Baxter - Premature Birth | Phase 3 | Terminated | Coordinación de Investigación en Salud, Mexico | 94 | 2011-05-01 | 2017-06-09 |
| Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer SMOF Kabiven - Pancreatic Cancer | Phase 3 | Terminated | National Center for Tumor Diseases, Heidelberg | 32 | 2010-03-01 | 2014-09-25 |
| Prader-Willi Syndrome and Appetite Sandostatin LAR - Hyperphagia, Prader-Willi Syndrome | Phase 3 | Terminated | University of British Columbia | 10 | 2004-08-01 | 2007-10-31 |
Prader-Willi Syndrome (5) · Obesity (2) · Anorexia Nervosa (1) · Bulimia (1) · Bulimia Nervosa (1) · Carcinoma, Squamous Cell (1) · Cholestasis (1) · Feeding and Eating Disorders (1) · Impulsive Behavior (1) · Intestinal Diseases (1) · Laryngeal Diseases (1) · Liver Diseases (1) · Pancreatic Neoplasms (1) · Premature Birth (1)
Pathological Conditions, Signs and Symptoms (12) · Signs and Symptoms (12) · Signs and Symptoms, Digestive (12) · Abnormalities, Multiple (5) · Chromosome Disorders (5) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Imprinting Disorders (5) · Intellectual Disability (5) · Nervous System Diseases (5) · Neurobehavioral Manifestations (5) · Neurologic Manifestations (5) · Nutrition Disorders (5) · Nutritional and Metabolic Diseases (5)
Fish Oils (2) · Soybean Oil (2) · soybean oil, phospholipid emulsion (2) · CKD732 (1) · Cetuximab (1) · Cisplatin (1) · Emulsions (1) · Fat Emulsions, Intravenous (1) · Naltrexone (1) · Parenteral Nutrition (1) · Radiotherapy (1) · SMOFlipid (1) · cyclic des-acyl ghrelin (6-13) (1) · fish oil triglycerides (1)
Aardvark Therapeutics, Inc. (2) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Coordinación de Investigación en Salud, Mexico (1) · Fresenius Kabi (1) · Hospices Civils de Lyon (1) · Johane Allard (1) · Millendo Therapeutics SAS (1) · National Center for Tumor Diseases, Heidelberg (1) · Rosemary Claire Roden (1) · University of British Columbia (1) · Zafgen, Inc. (1)
United States (6) · Canada (4) · Australia (3) · United Kingdom (3) · France (2) · South Korea (2) · Austria (1) · Belgium (1) · Germany (1) · Italy (1) · Mexico (1) · Netherlands (1) · Spain (1)
Dennis Kim, MD (1) · Didier Barnoud, MD (1) · Felix Keil, Prof.Dr. (1) · Jean-Pierre Chanoine, MD (1) · Johane P Allard, MD,FRCPC (1) · Rosemary C Roden, MD (1) · Steven A Abrams, MD (1)